4 research outputs found
Phase diagram of a random-anisotropy mixed-spin Ising model
We investigate the phase diagram of a mixed spin-1/2--spin-1 Ising system in
the presence of quenched disordered anisotropy. We carry out a mean-field and a
standard self-consistent Bethe--Peierls calculation. Depending on the amount of
disorder, there appear novel transition lines and multicritical points. Also,
we report some connections with a percolation problem and an exact result in
one dimension.Comment: 8 pages, 4 figures, accepted for publication in Physical Review
Tricritical behaviour in deterministic aperiodic Ising systems
We use a mixed-spin model, with aperiodic ferromagnetic exchange interactions
and crystalline fields, to investigate the effects of deterministic geometric
fluctuations on first-order transitions and tricritical phenomena. The
interactions and the crystal field parameters are distributed according to some
two-letter substitution rules. From a Migdal-Kadanoff real-space
renormalization-group calculation, which turns out to be exact on a suitable
hierarchical lattice, we show that the effects of aperiodicity are
qualitatively similar for tricritical and simple critical behaviour. In
particular, the fixed point associated with tricritical behaviour becomes fully
unstable beyond a certain threshold dimension (which depends on the
aperiodicity), and is replaced by a two-cycle that controls a weakened and
temperature-depressed tricritical singularity.Comment: Formatting improved. 7 pages, 2 figures (included). Journal reference
adde
Portuguese-Brazilian Evidence-Based Guideline on the Management of Hyperglycemia in Type 2 Diabetes Mellitus
Background: In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal was established to develop an evidence-based guideline for treatment of hyperglycemia in T2DM.
Methods: MEDLINE (via PubMed) was searched for randomized clinical trials, meta-analyses, and observational studies related to diabetes treatment. When there was insufficient high-quality evidence, expert opinion was sought. Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation and the level of evidence were determined using predefined criteria.
Results and conclusions: In non-pregnant adults, the recommended HbA1c target is below 7%. Higher levels are recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended at all phases of treatment. Metformin is the first choice when HbA1c is 6.5-7.5%. When HbA1c is 7.5-9.0%, dual therapy with metformin plus an SGLT2i and/or GLP-1RA (first-line antidiabetic agents, AD1) is recommended due to cardiovascular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple therapy should be considered when HbA1c remains above target. In patients with clinical or subclinical atherosclerosis, the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control. In stable heart failure with low ejection fraction ( 30 mL/min/1.73 m2, metformin plus an SGLT-2i is recommended to reduce cardiovascular mortality and heart failure hospitalizations and improve blood glucose control. In patients with diabetes-associated chronic kidney disease (CKD) (eGFR 30-60 mL/min/1.73 m2 or eGFR 30-90 mL/min/1.73 m2 with albuminuria > 30 mg/g), the combination of metformin and an SGLT2i is recommended to attenuate loss of renal function, reduce albuminuria and improve blood glucose control. In patients with severe renal failure, insulin-based therapy is recommended to improve blood glucose control. Alternatively, GLP-1RA, DPP4i, gliclazide MR and pioglitazone may be considered to reduce albuminuria. In conclusion, the current evidence supports individualizing anti-hyperglycemic treatment for T2DM.info:eu-repo/semantics/publishedVersio